Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
Cancer Immunology, Immunotherapy : CII
|
December 22, 2017
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
Tamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
Nature Reviews. Clinical Oncology
|
August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Cancer Immunology, Immunotherapy : CII
|
October 21, 2017
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
Tamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
David F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Clinical Genitourinary Cancer
|
December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>
Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
Cancer Immunology, Immunotherapy : CII
|
December 22, 2017
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
Tamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
Nature Reviews. Clinical Oncology
|
August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Howard L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Cancer Immunology, Immunotherapy : CII
|
October 21, 2017
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells
Tamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
The New England Journal of Medicine
|
June 8, 2010
Improved survival with ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Steven J O'Day, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
David F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.
Clinical Genitourinary Cancer
|
December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>
Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Page
of 7